Neurizon Raises AU$5 million to Advance ALS Clinical Trial Entry

Neurizon Therapeutics Limited (ASX: NUZ) announced that at the time of writing it has secured firm commitments to raise AU$5 million through an institutional placement at AU$0.12 per share. In addition, the Board and management will subscribe for AU$0.2 million, with part of this subject to shareholder approval in November 2025. The placement was strongly supported by both new and existing institutional investors.

Proceeds will strengthen the company’s balance sheet and fund preparations for entry into the HEALEY ALS Platform Trial in Q4 CY2025, pending FDA clearance of its IND. Funds will also support pre-clinical programs, GMP manufacturing of additional registration batches, regulatory filings, and working capital. The placement price represents a 14.3% discount to the last traded price. Settlement is expected on 23 September 2025, with allotment the following day. Petra Capital acted as sole lead manager and bookrunner.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com